Aspirin and stroke

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100

[2] [Anonymous], 1992, J Myocard. Ischemia

[3] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J]. LANCET, 1990, 335 (8693) : 827 - 838

[4] Hennekens C.H., 1987, EPIDEMIOLOGY MED

[5] ASPIRIN AND OTHER ANTIPLATELET AGENTS IN THE SECONDARY AND PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASE [J]. CIRCULATION, 1989, 80 (04) : 749 - 756

[6] Aspirin in the treatment and prevention of cardiovascular disease [J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1997, 18 : 37 - 49

[7] Aspirin as a therapeutic agent in cardiovascular disease - A statement for healthcare professionals from the American Heart Association [J]. CIRCULATION, 1997, 96 (08) : 2751 - 2753

[8] HENNEKENS CH, 1984, SMOKING AGING, P95

[9] ARACHIDONIC-ACID METABOLITES AND THE INTERACTIONS BETWEEN PLATELETS AND BLOOD-VESSEL WALLS [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (20) : 1142 - 1147

[10] PETO R, 1985, CIRCULATION, V72, P451

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100

[2] [Anonymous], 1992, J Myocard. Ischemia

[3] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J]. LANCET, 1990, 335 (8693) : 827 - 838

[4] Hennekens C.H., 1987, EPIDEMIOLOGY MED

[5] ASPIRIN AND OTHER ANTIPLATELET AGENTS IN THE SECONDARY AND PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASE [J]. CIRCULATION, 1989, 80 (04) : 749 - 756

[6] Aspirin in the treatment and prevention of cardiovascular disease [J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1997, 18 : 37 - 49

[7] Aspirin as a therapeutic agent in cardiovascular disease - A statement for healthcare professionals from the American Heart Association [J]. CIRCULATION, 1997, 96 (08) : 2751 - 2753

[8] HENNEKENS CH, 1984, SMOKING AGING, P95

[9] ARACHIDONIC-ACID METABOLITES AND THE INTERACTIONS BETWEEN PLATELETS AND BLOOD-VESSEL WALLS [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (20) : 1142 - 1147

[10] PETO R, 1985, CIRCULATION, V72, P451